Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD‐9)

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles